Immediate adverse reactions to chemotherapy: Experience of a large ambulatory treatment center

• DOI: 10.1200/jco.2006.24.18_suppl.8558
• Publication Date: 2020-04-17T13:29:03Z
• Authors: C. P. Escalante; J. H. Oh; D. D. Baum; M. Mante; A. Zalpour; S. Spivey; C. Stewart; J. Ensor; T. Grover; R. Freedman
• Keywords: Carboplatin; Adverse drug reaction

8558 Background: In recent years there has been a proliferation of Ambulatory Chemotherapy Treatment Centers (ATC). The incidence hypersensitivity and other immediate adverse drug reactions (IADR) in these ATC units have not well studied. We aim to describe our experience with IADR ATC. Methods: Retrospective chart review was conducted for all patients the Adverse Drug Reaction Report database (Maxsys II) year 2004. Data abstracted demographics, risk factors, clinical characteristics, outcomes IADR. Overall frequency different chemotherapeutic monoclonal agents infused obtained same period through pharmacy database. Results: 2004, 81,580 chemotherapy infusions were given 256 (0.31%) reported. mean age 55 45% males. most common drugs used fluorouracil (12.9%), paclitaxel (9.4%), docetaxel (6.1%), carboplatin (5.9%), gemcitabine (5.8%). table shows prevalent that led Common symptoms included flushing (52.3%), dyspnea (27.3%), chest discomfort (27%), pruritus (22.7%), hypertension (18.4%). Diphenhydramine (85.5%), hydrocortisone (37.1%), dexamethasone (17.2%) treatment factors previous allergy medications (43.4%), (19.5%), iodide (7.8%), allergies seafood (1.6%), allergic rhinitis (1.2%), urticaria asthma (0.8%). Most had their resumed completed (87.9%) on day. Discussion: rare. cases easily treated restarted However, they still pose significant burden cancer patients. Prospective studies are needed further evaluate identified offending outpatient settings. This will help develop pathways more effective prevention [Table: see text] No financial relationships disclose.